Nanjing Medical University and the Shanghai Institutes of Materia Medica and Nutrition & Health of the Chinese Academy of Sciences have prepared and tested 1,2,3,4-tetrahydropyridone compounds acting as Jumonji domain-containing protein 1C (JMJD1C; TRIP-8) inhibitors. As such, they are described as potentially useful for the treatment of cancer.
A patent from Centre National de la Recherche Scientifique (CNRS), McGill University and Sorbonne University discloses new acetylcholinesterase (AChE) inhibitors reported to be useful for the treatment of substance abuse and dependence, obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, obesity, Parkinson’s and Alzheimer’s disease.
Work at Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has led to the discovery of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Daegu-Gyeongbuk Medical Innovation Foundation and Provibio Co. Ltd. have identified new compounds described as potentially useful for the treatment of cancer and autoimmune diseases.
Cincinnati Children’s Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have jointly patented interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Mutations in the GNAO1 gene are tied to neurological disorders characterized by movement abnormalities and developmental delay. GNAO1 encodes the protein guanine nucleotide-binding protein G(o) subunit α, which is highly expressed in the brain. Among the mutations, R209H results in dystonia, choreoathetosis and developmental delay without seizures.
Researchers from Washington University School of Medicine performed studies to assess the role of ZBTB46, a repressive transcription factor and a marker for classical dendritic cells (DCs), in tumor angiogenesis.
Researchers from Excision Biotherapeutics Inc. and affiliated organizations have reported the development of a novel CRISPR/Cas9-mediated genome editing therapy – EBT-104 – for the treatment of latent herpes simplex virus 1 (HSV-1) keratitis.
RSS
